Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).
Patients with weak heart function who receive stem cell therapy shortly after a heart attack are at lower risk of developing heart failure and related hospital stays compared with standard care, finds ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, ...
Mayo Clinic researchers have identified a molecular "switch" in lung cells that helps them decide when to repair tissue and when to fight infection. This discovery could guide future regenerative ...
The U.S. health secretary said people should have access to experimental therapies including unregulated uses of stem cells. But some methods have resulted in blindness, tumors and other injuries. By ...
People who receive stem cell therapy within a week of their first heart attack have nearly a 60 per cent lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback